PURPOSE: In some reports, 5-fluorouracil has been associated with modest activity in patients with neuroendocrine tumors. Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates. We evaluated the efficacy of pemetrexed in a phase II study of patients with advanced neuroendocrine tumors. METHODS: Patients with metastatic neuroendocrine tumors (excluding small-cell carcinoma) were treated with pemetrexed administered intravenously at a dose of 500 mg/m(2) every 21 days. To reduce potential toxicity, patients also received folic acid, vitamin B12 supplementation, and peri-infusional treatment with dexamethasone. Patients were followed for response, toxicity, and survival. RESULTS: The study was designed with a total accrual goal of 32 patients. Due to lack of radiographic responses in patients during the study period, accrual was terminated at 17. However, one patient achieved a delayed partial response following discontinuation of pemetrexed. Ten patients were evaluable for biochemical response; five (50%) experienced >50% decrease in plasma chromogranin A. Among the 17 patients, 5 (29%) discontinued therapy due to treatment-related toxicity. The median overall survival was 12.1 months. CONCLUSION: Pemetrexed does not appear to have significant antitumor activity in patients with advanced neuroendocrine tumors. The limited antitumor activity and potential toxicity associated with pemetrexed mirrors experience with the majority of other cytotoxic agents in patients with neuroendocrine tumors. Investigation of novel, molecularly targeted agents may offer more promise in this disease.
PURPOSE: In some reports, 5-fluorouracil has been associated with modest activity in patients with neuroendocrine tumors. Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates. We evaluated the efficacy of pemetrexed in a phase II study of patients with advanced neuroendocrine tumors. METHODS:Patients with metastatic neuroendocrine tumors (excluding small-cell carcinoma) were treated with pemetrexed administered intravenously at a dose of 500 mg/m(2) every 21 days. To reduce potential toxicity, patients also received folic acid, vitamin B12 supplementation, and peri-infusional treatment with dexamethasone. Patients were followed for response, toxicity, and survival. RESULTS: The study was designed with a total accrual goal of 32 patients. Due to lack of radiographic responses in patients during the study period, accrual was terminated at 17. However, one patient achieved a delayed partial response following discontinuation of pemetrexed. Ten patients were evaluable for biochemical response; five (50%) experienced >50% decrease in plasma chromogranin A. Among the 17 patients, 5 (29%) discontinued therapy due to treatment-related toxicity. The median overall survival was 12.1 months. CONCLUSION:Pemetrexed does not appear to have significant antitumor activity in patients with advanced neuroendocrine tumors. The limited antitumor activity and potential toxicity associated with pemetrexed mirrors experience with the majority of other cytotoxic agents in patients with neuroendocrine tumors. Investigation of novel, molecularly targeted agents may offer more promise in this disease.
Authors: Matthew H Kulke; Haesook Kim; Keith Stuart; Jeffrey W Clark; David P Ryan; Michele Vincitore; Robert J Mayer; Charles S Fuchs Journal: Cancer Invest Date: 2004 Impact factor: 2.176
Authors: Matthew H Kulke; Haesook Kim; Jeffrey W Clark; Peter C Enzinger; Thomas J Lynch; Jeffrey A Morgan; Michele Vincitore; Ann Michelini; Charles S Fuchs Journal: Cancer Date: 2004-09-01 Impact factor: 6.860
Authors: Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544
Authors: Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: Giorgio V Scagliotti; Dong-M Shin; Hedy L Kindler; Michael J Vasconcelles; Uwe Keppler; Christian Manegold; Howard Burris; Ulrich Gatzemeier; Johannes Blatter; James T Symanowski; James J Rusthoven Journal: J Clin Oncol Date: 2003-04-15 Impact factor: 44.544
Authors: Yohann Loriot; Charles Ferte; Carlos Gomez-Roca; Christian Moldovan; Ratislav Bahleda; Marie Wislez; Jacques Cadranel; Jean-Charles Soria Journal: Clin Lung Cancer Date: 2009-09 Impact factor: 4.785
Authors: G A Kaltsas; J J Mukherjee; A Isidori; B Kola; P N Plowman; J P Monson; A B Grossman; G M Besser Journal: Clin Endocrinol (Oxf) Date: 2002-08 Impact factor: 3.478
Authors: John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman Journal: Gut Date: 2011-11-03 Impact factor: 23.059
Authors: Renata Ferrarotto; Laura Testa; Rachel P Riechelmann; Marina Sahade; Luiz T Siqueira; Frederico P Costa; Paulo M Hoff Journal: Rare Tumors Date: 2013-09-24